National Bank of Canada
BIO icon

National Bank of Canada’s Bio-Rad Laboratories Class A BIO Stock Holding History

National Bank of Canada’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.1M Buy
+90,000
New +$25.9M 0.02% 431
2024
Q3 		– Sell
-5,508
Closed -$1.45M – 2778
2024
Q2 		$1.45M Buy
5,508
+885
+19% +$257K ﹤0.01% 989
2024
Q1 		$1.3M Sell
4,623
-11,111
-71% -$3.65M ﹤0.01% 1084
2023
Q4 		$5.04M Sell
15,734
-2,397
-13% -$751K 0.01% 765
2023
Q3 		$6.44M Buy
18,131
+884
+5% +$341K 0.01% 733
2023
Q2 		$6.64M Buy
17,247
+15,760
+1,060% +$6.41M 0.01% 642
2023
Q1 		$712K Buy
1,487
+863
+138% +$404K ﹤0.01% 1146
2022
Q4 		$262K Sell
624
-794
-56% -$320K ﹤0.01% 1410
2022
Q3 		$605K Sell
1,418
-100
-7% -$49.9K ﹤0.01% 1113
2022
Q2 		$762K Sell
1,518
-6,491
-81% -$3.38M ﹤0.01% 1094
2022
Q1 		$4.51M Sell
8,009
-3,080
-28% -$1.86M 0.01% 643
2021
Q4 		$8.32M Buy
+11,089
New +$8.3M 0.03% 433

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

National Bank of Canada's BIO Position: Q1 2026 in Review

National Bank of Canada opened a new position in Bio-Rad Laboratories Class A (BIO) in Q1 2026: 90,000 shares worth $25.1M. The stake represents 0.02% of the portfolio and ranks #431 among its holdings. This is a return to the name: National Bank of Canada previously reported a position in BIO as recently as Q2 2024.

National Bank of Canada first reported a position in BIO in Q4 2021 and has held it in 12 quarters since. 392 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • National Bank of Canada held 90,000 shares of Bio-Rad Laboratories Class A worth $25.1M as of Q1 2026.
  • Bio-Rad Laboratories Class A was a new National Bank of Canada position in Q1 2026.
  • Bio-Rad Laboratories Class A made up 0.02% of National Bank of Canada's portfolio in Q1 2026, its #431 holding.
  • National Bank of Canada first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and has held it in 12 quarters since.
  • 392 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.